Literature DB >> 24520542

Steroid resistance in leukemia.

Darshan S Shah1, Raj Kumar1.   

Abstract

There are several types of leukemia which are characterized by the abnormal growth of cells from the myeloid or lymphoid lineage. Because of their lympholytic actions, glucocorticoids (GCs) are included in many therapeutic regimens for the treatment of various forms of leukemia. Although a significant number of acute lymphoblastic leukemia patients respond well to GC treatment during initial phases; prolonged treatments sometimes results in steroid-resistance. The exact mechanism of this resistance has yet not been completely elucidated, but a correlation between functional GC receptor expression levels and steroid-resistance in patients has been found. In recent years, several other mechanisms of action have been reported that could play an important role in the development of such drug resistances in leukemia. Therefore, a better understanding of how leukemic patients develop drug resistance should result in drugs designed appropriately to treat these patients.

Entities:  

Keywords:  Genes; Glucocorticoid; Leukemia; Mutations; Steroid resistant

Year:  2013        PMID: 24520542      PMCID: PMC3905587          DOI: 10.5493/wjem.v3.i2.21

Source DB:  PubMed          Journal:  World J Exp Med        ISSN: 2220-315X


  48 in total

1.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Authors:  Scott A Armstrong; Andrew L Kung; Meghann E Mabon; Lewis B Silverman; Ronald W Stam; Monique L Den Boer; Rob Pieters; John H Kersey; Stephen E Sallan; Jonathan A Fletcher; Todd R Golub; James D Griffin; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

Review 2.  Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia.

Authors:  W J E Tissing; J P P Meijerink; M L den Boer; R Pieters
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

Review 3.  Bcl-2-family proteins: the role of the BH3 domain in apoptosis.

Authors:  A Kelekar; C B Thompson
Journal:  Trends Cell Biol       Date:  1998-08       Impact factor: 20.808

4.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

5.  Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells.

Authors:  J Ramdas; W Liu; J M Harmon
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

6.  B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology.

Authors:  R A Soslow; R N Baergen; R A Warnke
Journal:  Cancer       Date:  1999-06-15       Impact factor: 6.860

Review 7.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

8.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

Authors:  Claudia D Baldus; Stephan M Tanner; Amy S Ruppert; Susan P Whitman; Kellie J Archer; Guido Marcucci; Michael A Caligiuri; Andrew J Carroll; James W Vardiman; Bayard L Powell; Steven L Allen; Joseph O Moore; Richard A Larson; Jonathan E Kolitz; Albert de la Chapelle; Clara D Bloomfield
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

9.  Glucocorticoid receptor levels predict response to treatment in human lymphoma.

Authors:  C D Bloomfield; A U Munck; K A Smith
Journal:  Prog Clin Biol Res       Date:  1984

Review 10.  Glucocorticoid receptor physiology.

Authors:  Marjet D Heitzer; Irene M Wolf; Edwin R Sanchez; Selma F Witchel; Donald B DeFranco
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

View more
  8 in total

1.  2-Deoxy-D-glucose Restore Glucocorticoid Sensitivity in Acute Lymphoblastic Leukemia via Modification of N-Linked Glycosylation in an Oxygen Tension-Independent Manner.

Authors:  Zaira Leni; Paulina Ćwiek; Valeriya Dimitrova; Andrea S Dulcey; Nicola Zamboni; Cedric Simillion; Geetha Rossi; Kurt Leibundgut; Alexandre Arcaro
Journal:  Oxid Med Cell Longev       Date:  2017-07-26       Impact factor: 6.543

2.  Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease.

Authors:  Masahiro Yasunaga; Shino Manabe; Yasuhiro Matsumura
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

Review 3.  Role of Phosphorylation in the Modulation of the Glucocorticoid Receptor's Intrinsically Disordered Domain.

Authors:  Raj Kumar; E Brad Thompson
Journal:  Biomolecules       Date:  2019-03-11

Review 4.  Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System.

Authors:  Cindy Strehl; Lisa Ehlers; Timo Gaber; Frank Buttgereit
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

5.  Zebrafish B cell acute lymphoblastic leukemia: new findings in an old model.

Authors:  Gilseung Park; Jessica Burroughs-Garcia; Clay A Foster; Ameera Hasan; Chiara Borga; J Kimble Frazer
Journal:  Oncotarget       Date:  2020-04-14

6.  The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia.

Authors:  Kinjal Shah; Mehreen Ahmed; Julhash U Kazi
Journal:  NPJ Precis Oncol       Date:  2021-02-17

Review 7.  Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia-The State-of-the-Art Knowledge and Future Prospects.

Authors:  Kamil Kośmider; Katarzyna Karska; Agata Kozakiewicz; Monika Lejman; Joanna Zawitkowska
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

Review 8.  Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia.

Authors:  Krzysztof Jędraszek; Marta Malczewska; Karolina Parysek-Wójcik; Monika Lejman
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.